Valnemulin downregulates nitric oxide, prostaglandin E2, and cytokine production via inhibition of NF-κB and MAPK activity

International Immunopharmacology

Volumn 9, Issue 7-8, 2009, Pages 810-816

  Zhang, Xuemei ^a,b   Li, Hongyu ^a   Feng, Haihua ^a   Xiong, Huanzhang ^b   Zhang, Lei ^a   Song, Yu ^a   Yu, Lu ^a   Deng, Xuming ^a  

^a JILIN UNIVERSITY   (China)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Cytokines; MAPKs; NF B; NO; PGE2; Valnemulin

Indexed keywords

ANTIBIOTIC AGENT; CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PLEUROMUTILIN; PROSTAGLANDIN E2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VALNEMULIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DITERPENES; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 67349243404     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.02.018     Document Type: Article

References (37)

1. Ialenti A., Moncada S., and Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 110 (1993) 701-706
2. Mongan L.C., Jones T., and Patrick G. Cytokine and free radical responses of alveolar macrophages in vitro to asbestos fibres. Cytokine 12 (2000) 1243-1247
3. Posadas I., Terencio M.C., Guillén I., Ferrándiz M.L., Coloma J., Payá M., et al. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 98-106
4. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 (1999) 1777-1782
5. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
6. Senftleben U., and Karin M. The IKK/NF-κB pathway. Crit Care Med 30 (2002) S18-26
7. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-734
8. Bayon Y., Ortiz M.A., Lopez-Hernandez F.J., Gao F., Karin M., and Pfahl M. Inhibition of IkappaB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol 23 (2003) 1061-1074
9. Guha M., and Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 13 (2001) 85-94
10. Wang X., and Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 272 (1996) 1347-1349
11. Schultz M.J., Speelman P., Zaat S., van Deventer S.J., and van der Poll T. Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 42 (1998) 1605-1609
12. Shapira L., Soskolne W.A., Houri Y., Barak V., Halabi A., and Stabholz A. Protection against endotoxic shock and lipopolysaccharide induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 64 (1996) 825-828
13. Cao X.Y., Dong M., Shen J.Z., Wu B.B., Wu C.M., Du X.D., et al. Tilmicosin and tylosin have anti-inflammatory properties via modulation of COX-2 and iNOS gene expression and production of cytokines in LPS-induced macrophages and monocytes. Int J Antimicrob Agents 27 (2006) 431-438
14. Purswani M., Eckert S., Arora H., Johann-Liang R., and Noel G.J. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for downregulation of cytokine mRNA transcription by trovafloxacin. J Antimicrob Chemother 46 (2000) 921-929
15. Ziegeler S., Raddatz A., Hoff G., Buchinger H., Bauer I., and Stockhausen A. Antibiotics modulate the stimulated cytokine response to endotoxin in a human ex vivo, in vitro model. Acta Anaesthesiol Scand 50 (2006) 1103-1110
16. Zhang X.M., Song Y., Ci X.X., An N., Fan J.W., and Cui J.Q. Effects of florfenicol on early cytokine responses and survival in murine endotoxemia. Int Immunopharmacol 8 (2008) 982-988
17. Koller K., and Schwarz F. Formulation of valnemulin [P]. US:6284792 (2001)
18. Hannan P.C., Windsor H.M., and Ripley P.H. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae. Res Vet Sci 63 (1997) 157-160
19. Long K.S., Hansen L.H., Jakobsen L., and Vester B. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob Agents Chemother 50 (2006) 1458-1462
20. Jordan F.T., Forrester C.A., Ripley P.H., and Burch D.G. In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum. Avian Dis 42 (1998) 738-745
21. Stipkovits L., Ripley P.H., Tenk M., Glávits R., Molnár T., and Fodor L. The efficacy of valnemulin (Econor) in the control of disease caused by experimental infection of calves with Mycoplasma bovis. Res Vet Sci 78 (2005) 207-215
22. Heilmann C., Jensen L., Jensen J.S., Lundstrom K., Windsor D., and Windsor H. Treatment of resistant Mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect 43 (2001) 234-238
23. Kim J.B., Han A.R., Park E.Y., Kim J.Y., Cho W., Lee J., et al. Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-κB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull 30 (2007) 2345-2351
24. Shi Y.Z., Tu Z.Z., Tang D.L., Zhang H.L., Liu M.D., Wang K.K., et al. The inhibition of LPS-induced production of inflammatory cytokines by HSP70 involves inactivation of the NF-κB pathway but not the MAPK pathways. Shock 26 (2006) 277-284
25. Chen C.C., and Wang J.K. p38 but not p44/42 mitogen-activated proteins kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol 55 (1999) 481-488
26. Takeda K., and Akira S. Regulation of innate immune responses by Toll-like receptors. Jpn J Infect Dis 54 (2001) 209-219
27. Kim N.D., Kim E.M., Kang K.W., Cho M.K., Choi S.Y., and Kim S.G. Ginsenoside Rg3 inhibits phenylephrine-induced vascular contraction through induction of nitric oxide synthase. Br J Pharmacol 140 (2003) 661-670
28. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
29. Mannel D.N., and Echtenacher B. TNF in the inflammatory response. Chem Immunol 74 (2000) 141-161
30. Glauser M.P. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 52 (1996) 9-17
31. Aggarwal B.B., and Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 7 (1996) 93-124
32. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O A., and Garra. IL-10 inhibits cytokine production by activated macrophages. J Immunol 146 (1991) 3444-3451
33. Berg D.J., Kühn R., Rajewsky K., Mül ler W., Menon S., Davidson N., et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96 (1995) 2339-2347
34. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
35. Caivano M. Role of MAP kinase cascades in inducing arginine transporters and nitric oxide synthetase in RAW 264.7 macrophages. FEBS Lett 429 (1998) 249-253
36. Meyer C.F., Wang X., Chang C., Templeton D., and Tan T.H. Interaction between c-Rel and the mitogen-activated protein kinase kinase 1 signaling cascade in mediating kappaB enhancer activation. J Biol Chem 271 (1996) 8971-8976
37. EMEA. The European agency for the evaluation of medicinal products, veterinary medicines evaluation unit: valnemulin, summary report [DB/OL] (1998). http://www.emea.europa.eu/vet/mrls/033998en.pdf http://www.emea.europa.eu/vet/mrls/033998en.pdf.